Comparative Pharmacology
Head-to-head clinical analysis: SONAZINE versus TREMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SONAZINE versus TREMIN.
SONAZINE vs TREMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sonazine is an antipsychotic agent that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, with additional antagonist activity at D1, alpha1-adrenergic, histaminergic H1, and muscarinic M1 receptors.
Trihexyphenidyl is a centrally acting anticholinergic agent that blocks muscarinic acetylcholine receptors in the basal ganglia, restoring the balance between dopaminergic and cholinergic activity, thereby reducing extrapyramidal symptoms.
10-20 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
1 mg orally 1-2 times daily, gradually increasing by 1 mg every 5-7 days up to 12 mg/day in divided doses. Maximum dose 12 mg/day.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours; clinical context: allows once-daily dosing, steady state achieved in 5-7 days, prolongation in elderly or hepatic impairment
Terminal elimination half-life: 16 hours (range 12–20 hours) in adults, supporting twice-daily dosing; 35 hours in elderly patients
Renal (70-80% as metabolites, <1% unchanged); fecal (15-20% via biliary elimination)
Renal: 40% unchanged; fecal: 60% as metabolites
Category C
Category C
Antipsychotic
Antipsychotic